Aptamer Group reports progress in partnerships and growth strategy at AGM

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will hold its Annual General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO10 5BR.

Dr Adam Hargreaves, Non-Executive Chairman will provide the following statement:

“I am delighted with the progress made by Aptamer Group. Since the fundraising of £2.6m in July this year, we have met our cost-base reduction targets, streamlined our scientific production capabilities, and executed our new commercial growth strategy to deliver optimised products of high quality to our growing customer base.

Attracting new partners has ensured that we are now working with the majority of the larger global pharmaceutical companies, alongside a wealth of diagnostic, healthcare, and niche biotech partners. Particular highlights have included the development of a vertical market platform in fibrosis, in which we are working with AstraZeneca; the progression toward human trials of our deodorant Optimer product with Unilever; and the successful production of an Optimer delivery conjugate to an undisclosed genetic medicines company, with which they are planning pre-clinical trials.

Our increased commercial traction has secured newly signed contracts, currently up to the value of £471,000, which will ensure that the Group’s cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period.

The Board looks forward to updating shareholders on further progress in due course.”

The AGM will provide no new material information. Results of the AGM will be announced to the London Stock Exchange and placed on the Aptamer Group’s website, in the usual way, as soon as practicable after the conclusion of the AGM.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer secures repeat contracts and new licensing deals

    Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases.

    Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

    Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection.

    Aptamer licences Optimer binders for swine vaccines

    Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health.

    Aptamer to present Optimer® liver targeting data at 2025 ASGCT

    Aptamer Group plc is set to unveil groundbreaking data on its Optimer® delivery vehicle for fibrotic liver disease at the 2025 ASGCT Annual Meeting.

    Aptamer Group publishes new Corporate Presentation and Investor Factsheet

    Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry.

    Aptamer Group reports revenue growth and solid cash position in H1 2025

    Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation.

      Search

      Search